DPPOS AD/ADRD Health Economics Evaluation

根据这一补充请求，在2022-2027年的DPPOS AD/ADRD中，我们建议延长我们的 以前的分析，以评估三个原始的较长期成本效用和成本效益 DPP干预，纳入关于资源利用、成本、健康状况/状况、 卫生公用事业和死亡率。为了支持这些经济分析，我们将继续收集 与干预措施和医疗保健相关的资源利用和费用的信息 研究之外的信息，以及关于健康结果、卫生效用和生存的信息。基于 在DPP/DPPOS期间收集的资源利用率和成本数据，我们将汇总 与最初的三项DPP随机干预措施中的每一项相关的医疗成本。AS 卫生与医学成本效益第二小组的建议(3)，医疗费用 将包括正规医疗保健部门的费用(例如，与实施和 维持DPP/DPPOS干预措施，以及研究外的医疗费用)， 非正规医疗保健部门(例如，参与者在锻炼上花费的时间成本和时间成本 护理费用)和非医疗保健部门的费用(例如，生产力下降所产生的费用)。 我们将估算与三个原始民进党各自相关的人均医疗成本 在DPP/DPPOS的时间过程中进行随机干预，并计算增量 ILS和MET干预相对于安慰剂的医疗成本以及来自 医疗保健部门的观点和社会的观点。

With this supplemental request, in DPPOS AD/ADRD during 2022-2027, we propose to extend our previous analyses to evaluate the longer-term cost-utility and cost-effectiveness of the three original DPP interventions by incorporating additional data on resource utilization, costs, health states/status, health utilities, and mortality. To support these economic analyses, we will continue to collect information on resource utilization and costs associated with the interventions and with medical care outside the study, and information on health outcomes, health utilities, and survival. Based on the resource utilization and cost data collected during DPP/DPPOS, we will summarize the total healthcare costs associated with each of the three original DPP randomized interventions. As recommended by the Second Panel on Cost-Effectiveness in Health and Medicine (3), healthcare costs will include costs in the formal healthcare sector (e.g., costs associated with implementing and maintaining the DPP/DPPOS interventions, and costs of medical care outside the study), those in the informal healthcare sector (e.g., costs of time spent by participants on exercising and costs of time spent by caregivers), and those in the non-healthcare sector (e.g., costs arising from lost productivity). We will estimate the mean per capita healthcare costs associated with each of the three original DPP randomized interventions over the time course of DPP/DPPOS, and calculate the incremental healthcare costs of the ILS and MET interventions relative to placebo and each other from a healthcare sector perspective and a societal perspective.